{"path":"Images/Pasted image 20240225132928.png","text":"KETAMINE Authors: Altered gene & protein Raymond Yan regulation: Urinary tract Revlewers: { GFAP, 1 BDNF expression infections Joshua Nicholas A pattern of Urinary Laura Byford-Richardson l nociception retention \" Michael Chong* ‘ Interstitial =MD at time of publication L NMDA receptor expression, P astrocytic activation, synaptic L neuropathic pain cystitis Abbreviations structure & function NMDA - N-methyl-D- aspartate —— . SHT - serotonin CLAECE IO 3 conduction in pri Y primary efferent ; . » - > —_— DA - dopamine weak ag:';‘;‘ﬂ\"j;::':r'sd and k- syinalcord faes Sedation NE - norepinephrine 2l P . GFAP - glial fibrillary acidic L, Y presynapticrelease of ) GABA and Substance P BDNF - brain-derived i e e NMDA receptor antagonist: Ach- acetyicholine non-competitive antagonism of -\\ excitation in higher CNS centers -, - A NMDA receptor = impaired (spinal, thalamic, limbic, cortical) Anlnis glutamate release aminobutyric acid Hallucinations Dissociative e Ketamine anesthesia elirium o Muscarinic recep‘mr antagonist: t Confusion Quick Facts antagonism of muscarinic A - receptor > impaired cholinergic v ACh response in periphery & CNS 1° Indication: Anesthesia transmission l 7 saiivary secretions Off-Label: Sedation/ Soioohimuseis 4 fidyeers relaxation Laryngospasm i i Bronchodilation (Route(s) of N concentration of DA/SHT in ey Bronchodilation Administration: IV/IM, synaptic junctions BO/BR/E ezl A Improved mood 4 cardiac stimulation Metabolism: 1°= hepatic Enhance central/peripheral / monoaminergic transmission: —> 1 sympathomimetic properties 1 cerebral blood flow B R PR 1 re-uptake of NE, DA, SHT Legend: Pathophysiology ~ Mechanism Sign/Symptom/Lab Finding Complications ‘ Published November 20, 2016 on www.thecalgaryguide.com","libVersion":"0.3.2","langs":"eng"}